Comparative Pharmacology
Head-to-head clinical analysis: BIMATOPROST versus ZIOPTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIMATOPROST versus ZIOPTAN.
BIMATOPROST vs ZIOPTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It binds to prostaglandin F (FP) receptors on ciliary muscle cells and trabecular meshwork cells, increasing uveoscleral outflow and possibly trabecular outflow of aqueous humor, thereby reducing intraocular pressure. It also directly stimulates the prostaglandin FP receptor, leading to increased matrix metalloproteinase activity and remodeling of the extracellular matrix in the ciliary body.
ZIOPTAN (tafluprost) is a prostaglandin analog that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
One drop of 0.01% or 0.03% ophthalmic solution instilled into the affected eye(s) once daily in the evening.
250 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateBimatoprost + Unoprostone
"Bimatoprost may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateBimatoprost + Hydrochlorothiazide
"Bimatoprost may increase the hypotensive activities of Hydrochlorothiazide."
Clinical Note
moderateBimatoprost + Epoprostenol
"Bimatoprost may increase the hypotensive activities of Epoprostenol."
Clinical Note
moderateVardenafil + Bimatoprost
"Vardenafil may increase the antihypertensive activities of Bimatoprost."
Terminal half-life: ~45 minutes (intravenous); after topical ocular administration, systemic half-life is similar due to rapid systemic clearance, with clinical effect lasting 24 hours due to ocular tissue binding
Terminal elimination half-life is approximately 2.8 to 4.5 hours in patients with normal renal function; no clinically significant accumulation occurs with twice-daily dosing.
Renal: <67% (unchanged and metabolites), Biliary/fecal: ~25%
Primarily renal excretion of unchanged drug (approximately 70-80% of an administered dose recovered in urine over 48 hours); biliary/fecal excretion accounts for 13% to 20% as parent drug and metabolites.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog